Investors purchased shares of Allergan PLC (NYSE:AGN) on weakness during trading on Friday. $154.92 million flowed into the stock on the tick-up and $134.07 million flowed out of the stock on the tick-down, for a money net flow of $20.85 million into the stock. Of all companies tracked, Allergan PLC had the 20th highest net in-flow for the day. Allergan PLC traded down ($3.41) for the day and closed at $249.61

Several analysts recently issued reports on AGN shares. Piper Jaffray Cos. reiterated a “cautious” rating and set a $236.00 price target (down previously from $238.00) on shares of Allergan PLC in a research report on Wednesday, May 11th. Guggenheim started coverage on shares of Allergan PLC in a research report on Monday, April 18th. They set a “neutral” rating on the stock. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $275.00 price target on shares of Allergan PLC in a research report on Monday, April 18th. Deutsche Bank AG reiterated a “buy” rating on shares of Allergan PLC in a research report on Monday, April 18th. Finally, Citigroup Inc. reiterated a “buy” rating and set a $285.00 price target on shares of Allergan PLC in a research report on Wednesday, May 11th. Seven research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Allergan PLC presently has an average rating of “Buy” and a consensus target price of $305.59.

The firm’s 50 day moving average is $244.00 and its 200-day moving average is $251.08. The company has a market capitalization of $98.83 billion and a PE ratio of 23.77.

Allergan PLC (NYSE:AGN) last released its quarterly earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, topping the Zacks’ consensus estimate of $3.34 by $0.01. During the same period in the prior year, the firm earned $4.41 EPS. The company earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC’s quarterly revenue was up 1.0% on a year-over-year basis. On average, analysts predict that Allergan PLC will post $13.99 EPS for the current year.

In related news, CFO Maria Teresa Hilado purchased 661 shares of the business’s stock in a transaction on Thursday, June 2nd. The stock was acquired at an average price of $241.57 per share, with a total value of $159,677.77. Following the purchase, the chief financial officer now directly owns 11,957 shares in the company, valued at $2,888,452.49. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Other large investors have made changes to their positions in the company. King Luther Capital Management Corp boosted its stake in shares of Allergan PLC by 359.2% in the fourth quarter. King Luther Capital Management Corp now owns 22,125 shares of the company’s stock worth $6,914,000 after buying an additional 17,307 shares during the period. Argent Capital Management LLC boosted its stake in shares of Allergan PLC by 1.9% in the fourth quarter. Argent Capital Management LLC now owns 165,812 shares of the company’s stock worth $51,816,000 after buying an additional 3,154 shares during the period. American International Group Inc. boosted its stake in shares of Allergan PLC by 1.5% in the fourth quarter. American International Group Inc. now owns 164,589 shares of the company’s stock worth $51,435,000 after buying an additional 2,511 shares during the period. Utah Retirement Systems boosted its stake in shares of Allergan PLC by 0.3% in the fourth quarter. Utah Retirement Systems now owns 70,461 shares of the company’s stock worth $22,019,000 after buying an additional 200 shares during the period. Finally, State of Tennessee Treasury Department boosted its stake in shares of Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock worth $145,669,000 after buying an additional 268,357 shares during the period.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.